Results
Tumor response
- Quality of Life (QoL): 90% Palliative Performance Scale (PPS) at each time point
- Median time to progression for patients that progressed: 2.5 months (range: 0.8-6)
- Overall survival (OS): 14 months (range: 1.3-25) during assessed period
- Median time to follow up: 14 months
- Complications and side effects: ADETs were performed with no complications
Observed side effects (mild or moderate intensity) were: Pain in 32% of patients, increase of transaminase levels in 20% and fever in 14%, whereas 30% of patients did not complain any adverse event.
| CR | 28% | 24% | 18% |
| PR | 48% | 38% | 44% |
| SD | 8% | 19% | 21% |
| PD | 16% | 19% | 18% |
Conclusion
The therapy of unresectable mCRC with ADET using LifePearl® loaded with irinotecan was effective in tumor response and resulted in mild toxicity, and good QoL. According to the authors these results are very similar to those previously reported with drug eluting beads.
